Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug-Drug Interactions via Mechanism-Based Cytochrome P450 Inactivation: Points to Consider for Risk Assessment from In Vitro Data and Clinical Pharmacologic Evaluation

1 Jun 2007

Abstract excerpt

This commentary discusses the approaches to, and key considerations in the in vitro-in vivo extrapolation of drug-drug interactions (DDI) resulting from mechanism-based inactivation (MBI) of cytochrome P450 (CYP) enzymes and clinical pharmacologic implications. In vitro kinetic assessment and prediction of DDI produced via reversible inhibition and MBI rely on operationally and conceptually distinct approaches....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Treatment and Pharmacology
Share to Innovative Microfluidic and Catalytic Techniques Innovation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pharmacogenetics and Drug Metabolism

Source

Identifiers

PMID: 17584016
DOI: 10.2174/138920007780866861

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug-Drug Interactions via Mechanism-Based Cytochrome P450 Inactivation: Points to Consider for Risk Assessment from In Vitro Data and Clinical Pharmacologic EvaluationPMID 17584016Read ↗

Reaction phenotyping to assess victim drug-drug interaction risks.Semantic proximity Read ↗

The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.Semantic proximity Read ↗

Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro ModelsSemantic proximity Read ↗

Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.Semantic proximity Read ↗

In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises.Semantic proximity Read ↗

In Vitro Reaction Phenotyping and Projection of Drug Interactions Mediated by Cytochrome P450 Enzymes for Central Nervous System Drugs as Victims: Implications for Safety in Vulnerable Populations.Semantic proximity Read ↗

Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment.Semantic proximity Read ↗

Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.Semantic proximity Read ↗

Cytochrome P450 reaction phenotyping: State of the art.Semantic proximity Read ↗

Targeted but Troubling: CYP450 Inhibition by Kinase and PARP Inhibitors and Its Clinical ImplicationsSemantic proximity Read ↗

Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment.Semantic proximity Read ↗

In vitro ADME phenotyping in drug discovery: current challenges and future solutions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.